Fluorescent tracer agents coupled with transdermal detection technology enable physiological monitoring.
Bright fluorescent agents designed not to interact with the body are sensed through the skin.
New clinical applications for fluorescent tracer agent-based systems are in development.
Clinical and preclinical studies are underway to advance the use of fluorescence to measure and monitor disease progression.
Composition of matter, algorithm, and method patents are a platform for continued innovation.
Leading academic centers, research institutes, contract research organizations and pharmaceutical companies worldwide rely on MediBeacon technology.
Clinically practical solutions which can reduce the cost of healthcare while improving the standard of care are the goal.
Fluorescent agents engineered to not interact with the body have the potential to enable measurement and monitoring of vital organ systems.
Measurement of GFR is widely accepted as the best indicator of kidney function. A clinically practical and accurate real-time point of care methodology holds promise.
Increased intestinal permeability is implicated in inflammatory bowel disease. Rapid assessment of gut barrier function is a focus.
Fluorescent agent angiography has the potential to aid in diagnosis and monitoring of vasculature leakage seen in Diabetic Retinopathy, Macular Degeneration and Retinal Vasculitis.
Intraoperative identification of ureter or ureteral injury is critical to prevent serious complications. Use of fluorescent agents could potentially aid in surgical visualization.
Potential medical applications for fluorescent tracer agent-based systems are wide ranging and target important unmet patient needs.
Fluorescent tracer agent-based systems target growing unmet patient needs globally.
Scientists who have made the application of fluorescent technology in healthcare their life’s work are behind MediBeacon’s medical innovations.
Investment in fluorescence-based systems target multiple multi-billion dollar unmet medical needs.
Technology whose development began inside leading medical technology companies is nearing human application today.
Industry leaders including scientists and clinicians are behind fluorescence enabled technology that has the potential to impact global health.
Our approach to quality concentrates on the integrity of processes and preventive measures.
The latest developments are global in scope.
BioSTL fosters collaborative efforts and builds regional infrastructure to achieve St. Louis’ potential in biosciences. BioSTL issued the following News Update on August 27, 2012.
MediBeacon LLC, a new St. Louis-based optical diagnostic company has announced its initial round of funding.
BioSTL’s affiliate, the BioGenerator, provided business assistance and funding to MediBeacon through its i6 Challenge program that supports the launch of local bioscience startups. MediBeacon also received funding from St. Louis Development Corporation and Missouri Technology Corporation.
MediBeacon will utilize the shared laboratory facilities of the BioGenerator Accelerator Labs, and will have offices at the Center for Emerging Technologies.
Please see the attached press release from MediBeacon and coverage in the attached article from last week’s St. Louis Business Journal.
1100 Corporate Square Drive
St. Louis, MO 63132
P: (314) 269-5808
P: +49 (0)621-150283-15
Huadong Medicine Co., Ltd
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
*MediBeacon products are in various stages of clinical development and are not yet approved for human use.
**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.